Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

Shares of Bristol Myers Squibb Co. slid 3.42% to $46.86 Friday, on what proved to be an all-around dismal trading session for ...

What Happened? Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a ...

The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of ...

Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Bristol-Myers Squibb, in partnership with K36 Therapeutics, updated progress on their Phase 1 trial of KTX-1001 for relapsed ...

AstraZeneca spinout Dizal Pharmaceuticals won an FDA accelerated approval for sunvozertinib for previously treated EGFR ex 20-mutated non-small cell lung cancer. To be marketed as Zegfrovy, the oral ...

This was the stock's third consecutive day of gains.

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

The number of employees laid off and companies letting people go increased year over year during the first half of 2025. BioSpace recaps the five largest layoff rounds, including cuts at Bayer, BMS ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Bristol Myers Squibb outperformed major indexes, closing 1.32% higher at $47.66, while peers lagged. The company’s stock ...